Landscape of inflammatory bowel disease in Singapore

Low, Daren; Swarup, Nidhi; Okada, Toshiyuki; Mizoguchi, Emiko

doi:10.5217/ir.2021.00089

Cited by 7 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Asia, our projections indicate that IBD incidence will continue to rise until reaching a plateau by 2030. Additionally, high-income countries in Asia are already in the Compounding Prevalence stage and are transitioning to Prevalence Equilibrium [ 49 , 56 , 63 ]. Although the incidence has plateaued, the annual number of cases in high-income countries is expected to decrease, potentially due to demographic shifts resulting from declining fertility rates in these countries.…”

Section: Discussionmentioning

confidence: 99%

Evolving Trends and Burden of Inflammatory Bowel Disease in Asia, 1990–2019: A Comprehensive Analysis Based on the Global Burden of Disease Study

Chen,

Xiang,

Xia

et al. 2023

J Epidemiol Glob Health

View full text Add to dashboard Cite

Background Asia’s inflammatory bowel disease (IBD) burden has rapidly increased recently, but the epidemiological trends in Asia remain unclear. We report IBD’s incidence, prevalence, mortality, and Disability-Adjusted Life Years (DALY) in 52 Asian countries from 1990 to 2019. Methods Data from the Global Burden of Disease 2019 were analyzed for IBD burden across 52 countries, using metrics like incidence, prevalence, mortality rates, and DALY. The epidemiological trend of IBD from 1990 to 2019 was assessed with the Joinpoint and APC methods. Decomposition and frontier analyses examined factors behind IBD case and death changes. The NORPRED forecasted Asia's morbidity and mortality trends from 2019 to 2044. Results From 1990 to 2019, The incidence and prevalence of IBD increased in Asia, while mortality and DALY decreased. East Asia had the highest increase in disease burden. IBD incidence was highest among the 30–34 age group, with prevalence peaking in the 45–49 age group. In high-income regions, IBD peak age shifted to younger groups. Decompose analysis showed population growth as the primary factor for the increasing IBD cases in Asia. NORDPRED model predicted a continued IBD burden increase in Asia over the next 25 years. Conclusions Between 1990 and 2019, ASIR and ASPR of IBD in Asia increased, while ASMR and ASDR decreased. Due to population growth and aging, the IBD burden is expected to rise over the next 25 years, particularly in East Asia.

show abstract

Section: Discussionmentioning

confidence: 99%

Evolving Trends and Burden of Inflammatory Bowel Disease in Asia, 1990–2019: A Comprehensive Analysis Based on the Global Burden of Disease Study

Chen,

Xiang,

Xia

et al. 2023

J Epidemiol Glob Health

View full text Add to dashboard Cite

show abstract

“…IMIDs can be classified into three groups based on the affected organs. Inflammatory bowel diseases (IBD: Crohn's disease and ulcerative colitis), inflammatory arthritides (rheumatoid arthritis and ankylosing spondylitis), and psoriasis are IMIDs that mainly affect the gut, joints, and skin, respectively (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15). Studies have shown that each IMID is associated with a higher risk of depression and anxiety in the general population with effect sizes similar to that of T2DM (16)(17)(18)(19).…”

Section: Introductionmentioning

confidence: 99%

Association of immune-mediated inflammatory diseases with depression and anxiety in patients with type 2 diabetes: A nationwide population-based study

et al. 2023

View full text Add to dashboard Cite

ObjectivePatients with type 2 diabetes (T2DM) are at a high risk of developing depression and anxiety. To better stratify the risk, we aimed to assess whether the presence of immune-mediated inflammatory diseases (IMIDs) confers a higher risk of depression and anxiety in these patients.MethodsPatients with T2DM without prior depression or anxiety who underwent national health examination between 2009 and 2012 (n = 1,612,705) were enrolled from the nationwide health check-up data from Korean National Health Insurance Service. The outcome events were incident depression and anxiety, defined as International Classification of Diseases, 10th Revision codes F32–F33 and F40–F41, respectively. Multivariable Cox proportional hazard regression analyses were conducted to estimate the adjusted hazard ratio (aHR) and 95% confidence interval (CI) according to the existence of IMIDs.ResultsOver an average follow-up time of 6.4 years, existence of gut IMIDs was associated with a higher risk of depression (aHR: 1.28 [95% CI: 1.08–1.53]) and anxiety (1.22 [1.06–1.42]). Existence of joint IMIDs was associated with a higher risk of depression (1.34 [1.31–1.37]) and anxiety (1.31 [1.29–1.34]). Existence of skin IMID was associated with a higher risk of depression (1.18 [1.14–1.23]) and anxiety (1.13 [1.09–1.16]). The effect sizes of IMIDs on depression and anxiety were larger in those with ≥ 2 IMIDs (1.42 [1.19–1.69] and 1.49 [1.29–1.72], respectively) than in those with one IMID (1.30 [1.27–1.32] and 1.26 [1.24–1.28], respectively).ConclusionIn patients with T2DM, presence of IMIDs was associated with a higher risk of depression and anxiety. More stringent attention and screening for anxiety and depression should be encouraged in patients with T2DM and comorbid IMIDs due to clinical implications of psychological distress on patient-reported outcomes and prognosis.

show abstract

“…The incidence of inflammatory bowel disease (IBD) is increasing rapidly in many Asian countries [1][2][3]. Because IBD is an immune-mediated chronic disease, the majority of patients require lifelong treatment with immunosuppressive agents, such as thiopurines, methotrexate, biologics, and small molecule agents [4].…”

Section: Introductionmentioning

confidence: 99%

Vaccination strategies for Korean patients with inflammatory bowel disease

Lee

Kim

2022

Korean J Intern Med

View full text Add to dashboard Cite

Patients with inflammatory bowel disease (IBD) are vulnerable to vaccine-preventable infectious diseases. Immunosuppressive drugs, which are often used to manage IBD, may increase this vulnerability and attenuate vaccine efficacy. Thus, healthcare providers should understand infectious diseases and schedule vaccinations for them to reduce the infection-related burden of patients with IBD. All patients with IBD should be assessed in terms of immunity to vaccine-preventable diseases at the time of IBD diagnosis, and be vaccinated appropriately. Vaccination is becoming more important because of the unprecedented coronavirus disease 2019 (COVID-19) global health crisis. This review focuses on recent updates to vaccination strategies for Korean patients with IBD.

show abstract

Landscape of inflammatory bowel disease in Singapore

Cited by 7 publications

References 26 publications

Evolving Trends and Burden of Inflammatory Bowel Disease in Asia, 1990–2019: A Comprehensive Analysis Based on the Global Burden of Disease Study

Evolving Trends and Burden of Inflammatory Bowel Disease in Asia, 1990–2019: A Comprehensive Analysis Based on the Global Burden of Disease Study

Association of immune-mediated inflammatory diseases with depression and anxiety in patients with type 2 diabetes: A nationwide population-based study

Vaccination strategies for Korean patients with inflammatory bowel disease

Contact Info

Product

Resources

About